Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Development of Bone Targeted Drug Delivery Technologies
share announcement

Development of Bone Targeted Drug Delivery Technologies

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 13729

Special Issue Editor

Prof. Dr. Hsin-I. Chang

E-Mail Website
Guest Editor
Department of Biochemical Science and Technology, National Chia Yi University, No. 300, Syuefu Rd, Chiayi City 60004, Taiwan
Interests: bone drug delivery system; osteoarthritis; liposomal formulation; spinal degeneration; tissue engineering

Special Issue Information

Dear Colleagues,

The skeleton provides support and structure to the body. As people age, they start to lose their cartilage and bone mass. Therefore, chronic, degenerative spine, bone or joint diseases are common problems among the elderly. The current therapeutic strategy for degenerative spine, bone or joint diseases is focused on reducing pain and minimizing structural and symptomatic progression in order to delay surgery therapy as long as possible. There is no cure for these bone diseases, and hence, tissue engineering, cell therapy, and local drug delivery may provide more effective therapeutics. The design of a drug delivery system is based on drug properties, access to a disease location, and therapeutic effectiveness. Until now, bone-targeted drug delivery technologies have tended to focus on local delivery systems (or site-specific delivery systems). At present, we are particularly taking an interest in manuscripts that report bone-targeted drug delivery systems and which can efficiently bring drugs (or cells) to bone or cartilage tissues. Reviews that summarize the results of in vitro and in vivo studies using bone targeted drug delivery systems to predict a response therapy are welcome. Moreover, papers involving attractive drug delivery technologies such as nanodevices, bioadhesive systems, implants, microfabricated systems, cell encapsulation devices, and novel bone targeted drug delivery systems would be of great interest. Main topics include but are not limited to:

  • Cell therapy in spine, bone, and cartilage;
  • The application of tissue engineering in spine, bone, and cartilage;
  • Drug delivery in spine, bone, and cartilage.

Prof. Dr. Hsin-I. Chang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bone
  • cartilage
  • drug delivery
  • tissue engineering
  • bone and cartilage degeneration
  • osteoporosis
  • degenerative disc disease
  • cell therapy

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 3489 KiB  
Communication
Therapeutic Effect of Benidipine on Medication-Related Osteonecrosis of the Jaw
by Ken Matsunaka, Mikio Imai, Koma Sanda, Noriyuki Yasunami, Akihiro Furuhashi, Ikiru Atsuta, Hiroko Wada and Yasunori Ayukawa
Pharmaceuticals 2022, 15(8), 1020; https://doi.org/10.3390/ph15081020 - 18 Aug 2022
Cited by 1 | Viewed by 1689
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is an intractable disease that is typically observed in patients with osteoporosis or tumors that have been treated with either bisphosphonate (BP) or antiangiogenic medicine. The mechanism of MRONJ pathogenesis remains unclear, and no effective definitive treatment [...] Read more.
Medication-related osteonecrosis of the jaw (MRONJ) is an intractable disease that is typically observed in patients with osteoporosis or tumors that have been treated with either bisphosphonate (BP) or antiangiogenic medicine. The mechanism of MRONJ pathogenesis remains unclear, and no effective definitive treatment modalities have been reported to date. Previous reports have indicated that a single injection of benidipine, an antihypertensive calcium channel blocker, in the vicinity of a tooth extraction socket promotes wound healing in healthy rats. The present study was conducted to elucidate the possibility of using benidipine to promote the healing of MRONJ-like lesions. In this study, benidipine was administered near the site of MRONJ symptom onset in a model rat, which was then sacrificed two weeks after benidipine injection, and analyzed using histological sections and CT images. The analysis showed that in the benidipine groups, necrotic bone was reduced, and soft tissue continuity was recovered. Furthermore, the distance between epithelial edges, length of necrotic bone exposed in the oral cavity, necrotic bone area, and necrotic bone ratio were significantly smaller in the benidipine group. These results suggest that a single injection of benidipine in the vicinity of MRONJ-like lesions can promote osteonecrotic extraction socket healing. Full article
(This article belongs to the Special Issue Development of Bone Targeted Drug Delivery Technologies)
►▼ Show Figures

Graphical abstract

16 pages, 3025 KiB  
Article
Development of Astaxanthin-Loaded Nanosized Liposomal Formulation to Improve Bone Health
by Hsin-I. Chang, Chu-Wen Shao, Evelyn Huang and Kuo-Yuan Huang
Pharmaceuticals 2022, 15(4), 490; https://doi.org/10.3390/ph15040490 - 18 Apr 2022
Cited by 7 | Viewed by 2156
Abstract
Astaxanthin is a xanthophyll carotenoid commonly found in marine organisms. Due to its super antioxidative ability, astaxanthin has been widely applied as a human nutraceutical supplement for health benefits. In order to enhance the bioavailability of astaxanthin, we used soybean phosphatidylcholine to encapsulate [...] Read more.
Astaxanthin is a xanthophyll carotenoid commonly found in marine organisms. Due to its super antioxidative ability, astaxanthin has been widely applied as a human nutraceutical supplement for health benefits. In order to enhance the bioavailability of astaxanthin, we used soybean phosphatidylcholine to encapsulate astaxanthin for liposomal formation. The physical properties of astaxanthin (asta)-loaded liposomes were determined by particle size, encapsulation efficiency and polydispersity index. The results revealed that the particle sizes of asta-loaded liposomes with various concentrations exhibited mean diameters in the range of 109 to 134 nm and had a narrow PDI value. As expected, the entrapment efficiency of liposomes loaded with a low concentration of astaxanthin (0.05 μg/mL) was 89%, and that was reduced to 29% for 1.02 μg/mL asta loading. Alizarin red staining and calcium content measurement showed that there was a significant reduction in calcium deposition for 7F2 osteoblasts treated with asta-loaded liposomes (0.25–1.02 μg/mL) in comparison with the cells treated with drug-free liposomes and mineralization medium (MM). Although liposomal formulation can reduce the cytotoxicity of astaxanthin and possess antioxidant, anti-inflammatory and anti-osteoclastogenic activities in RAW264.7 macrophages, asta-loaded liposomes with high concentrations may suppress ALP activity and mineralization level in 7F2 osteoblasts. Therefore, astaxanthin extract may be able to protect bones against oxidative stress and inflammation through liposomal formulation. Full article
(This article belongs to the Special Issue Development of Bone Targeted Drug Delivery Technologies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

27 pages, 4469 KiB  
Review
Composing On-Program Triggers and On-Demand Stimuli into Biosensor Drug Carriers in Drug Delivery Systems for Programmable Arthritis Therapy
by Yan Yik Lim, Ahmad Mujahid Ahmad Zaidi and Azizi Miskon
Pharmaceuticals 2022, 15(11), 1330; https://doi.org/10.3390/ph15111330 - 27 Oct 2022
Cited by 12 | Viewed by 1884
Abstract
Medication in arthritis therapies is complex because the inflammatory progression of rheumatoid arthritis (RA) and osteoarthritis (OA) is intertwined and influenced by one another. To address this problem, drug delivery systems (DDS) are composed of four independent exogenous triggers and four dependent endogenous [...] Read more.
Medication in arthritis therapies is complex because the inflammatory progression of rheumatoid arthritis (RA) and osteoarthritis (OA) is intertwined and influenced by one another. To address this problem, drug delivery systems (DDS) are composed of four independent exogenous triggers and four dependent endogenous stimuli that are controlled on program and induced on demand, respectively. However, the relationships between the mechanisms of endogenous stimuli and exogenous triggers with pathological alterations remain unclear, which results in a major obstacle in terms of clinical translation. Thus, the rationale for designing a guidance system for these mechanisms via their key irritant biosensors is in high demand. Many approaches have been applied, although successful clinical translations are still rare. Through this review, the status quo in historical development is highlighted in order to discuss the unsolved clinical difficulties such as infiltration, efficacy, drug clearance, and target localisation. Herein, we summarise and discuss the rational compositions of exogenous triggers and endogenous stimuli for programmable therapy. This advanced active pharmaceutical ingredient (API) implanted dose allows for several releases by remote controls for endogenous stimuli during lesion infections. This solves the multiple implantation and local toxic accumulation problems by using these flexible desired releases at the specified sites for arthritis therapies. Full article
(This article belongs to the Special Issue Development of Bone Targeted Drug Delivery Technologies)
►▼ Show Figures

Graphical abstract

24 pages, 886 KiB  
Review
Bone Tissue Engineering in the Treatment of Bone Defects
by Nannan Xue, Xiaofeng Ding, Rizhong Huang, Ruihan Jiang, Heyan Huang, Xin Pan, Wen Min, Jun Chen, Jin-Ao Duan, Pei Liu and Yiwei Wang
Pharmaceuticals 2022, 15(7), 879; https://doi.org/10.3390/ph15070879 - 17 Jul 2022
Cited by 70 | Viewed by 7312
Abstract
Bones play an important role in maintaining exercise and protecting organs. Bone defect, as a common orthopedic disease in clinics, can cause tremendous damage with long treatment cycles. Therefore, the treatment of bone defect remains as one of the main challenges in clinical [...] Read more.
Bones play an important role in maintaining exercise and protecting organs. Bone defect, as a common orthopedic disease in clinics, can cause tremendous damage with long treatment cycles. Therefore, the treatment of bone defect remains as one of the main challenges in clinical practice. Today, with increased incidence of bone disease in the aging population, demand for bone repair material is high. At present, the method of clinical treatment for bone defects including non-invasive therapy and invasive therapy. Surgical treatment is the most effective way to treat bone defects, such as using bone grafts, Masquelet technique, Ilizarov technique etc. In recent years, the rapid development of tissue engineering technology provides a new treatment strategy for bone repair. This review paper introduces the current situation and challenges of clinical treatment of bone defect repair in detail. The advantages and disadvantages of bone tissue engineering scaffolds are comprehensively discussed from the aspect of material, preparation technology, and function of bone tissue engineering scaffolds. This paper also summarizes the 3D printing technology based on computer technology, aiming at designing personalized artificial scaffolds that can accurately fit bone defects. Full article
(This article belongs to the Special Issue Development of Bone Targeted Drug Delivery Technologies)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop